CLINICAL TRIAL / NCT05636618

Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors

  • Interventional
  • Recruiting
  • NCT05636618

A Phase I/IIa First-in-Human Study of [212Pb]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors

This study is Phase I/IIa First-in-Human Study of [212Pb]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors